deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT05274451

A Study to Investigate LYL797 in Adults With Solid Tumors

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies

Sponsor: Lyell Immunopharma, Inc.

Conditions Advanced Breast Cancer Advanced Lung Carcinoma Endometrial Cancer Endometrioid Tumor Fallopian Tube Cancer High Grade Serous Carcinoma NSCLC NSCLC Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Non Small Cell Lung Cancer Metastatic Non-Small Cell Carcinoma of Lung, TNM Stage 4 Non-small Cell Lung Cancer Ovarian Cancer Ovarian Epithelial Cancer Platinum-resistant Ovarian Cancer Primary Peritoneal Carcinoma Recurrent Breast Cancer Recurrent NSCLC Relapse/Recurrence Relapsed Cancer TNBC - Triple-Negative Breast Cancer Triple Negative Breast Cancer
Interventions LYL797
Updated 19 times since 2022 Last updated: Jun 27, 2025 Started: Mar 29, 2022 Primary completion: Nov 27, 2024 Completion: Nov 27, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Pipeline Reprioritization

Other terminated trials from Lyell Immunopharma, Inc.

More terminations from Lyell Immunopharma, Inc.

Other Advanced Breast Cancer trials with similar outcome

Browse all Advanced Breast Cancer trials

A PHASE1 clinical study on Advanced Breast Cancer and Advanced Lung Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Lyell Immunopharma, Inc. and has accumulated 19 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Aug 2025 · 8 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Aug 2025 — Sep 2025 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  3. Dec 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Oct 2024 — Dec 2024 [monthly]

    Recruiting PHASE1

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

▶ Show 14 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  2. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  3. Feb 2024 — Apr 2024 [monthly]

    Recruiting PHASE1

  4. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

  5. Sep 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  6. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  7. May 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

  8. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1

  9. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  10. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1

  11. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

  12. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  13. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  14. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lyell Immunopharma, Inc.
Data source: Lyell Immunopharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chicago, United States , Detroit, United States , Houston, United States , Jacksonville, United States , Miami, United States , Milwaukee, United States , Nashville, United States , New Haven, United States , New York, United States , Oklahoma City, United States and 8 more locations